A5102818589- HIV/AIDS drug development and treatment
- HIV/AIDS Research and Interventions
- HIV Research and Treatment
- HIV-related health complications and treatments
- Pneumocystis jirovecii pneumonia detection and treatment
- Pharmaceutical studies and practices
- Medication Adherence and Compliance
- Antibiotics Pharmacokinetics and Efficacy
- Intramuscular injections and effects
- Pharmaceutical Practices and Patient Outcomes
- Health Systems, Economic Evaluations, Quality of Life
ViiV Healthcare (United Kingdom)
2020-2023
Triangle
2020-2022
Mortimer Market Centre
2009
Camden and Islington NHS Foundation Trust
2001
Background: ATLAS (NCT02951052), a phase 3, multicenter, open-label study, demonstrated that switching to injectable cabotegravir (CAB) with rilpivirine (RPV) long-acting dosed every 4 weeks was noninferior at week (W) 48 continuing three-drug daily oral current antiretroviral therapy (CAR). Results from the W 96 analysis are presented. Methods and design: Participants completing 52 of were given option withdraw, transition ATLAS-2M (NCT03299049), or enter an Extension Phase continue...
To characterize cabotegravir population pharmacokinetics using data from phase 1, 2 and 3 studies evaluate the association of intrinsic extrinsic factors with pharmacokinetic variability.Analyses were implemented in NONMEM R. Concentrations below quantitation limit modelled likelihood-based approaches. Covariate relationships evaluated forward addition (P < .01) backward elimination .001) The impact each covariate on trough peak concentrations was through simulations. External validation...
Abstract We report the safety and pharmacokinetic properties of HIV‐1 maturation inhibitor GSK3739937 (GSK'937) in healthy participants. This was a phase I, first‐in‐human, double‐blind, randomized, placebo‐controlled, single‐ (part 1) multiple‐ 2) dose escalation study with an additional open‐label relative bioavailability food effect 3). Participants received oral ascending single doses (10–800 mg) part 1, up to 18 once‐daily 25‐ 100‐mg or 3 once‐weekly 500‐mg 2, as powder‐in‐bottle tablet...
Objectives People with HIV (PWHIV) are likely to need therapies for comorbidities as they age. We assessed risk of drug–drug interactions (DDIs) in PWHIV. Methods The Climate‐HIV electronic recording system was used cross‐sectionally analyse records from PWHIV aged ≥ 18 years attending four UK units a current antiretroviral (ARV) prescription February 2018. Antiretroviral and non‐ARV medications were categorized by clinical significance DDIs (University Liverpool DDI tool). Potential...
Serious adverse events and medication errors are common in clinical practice associated with significant morbidity mortality. Management of HIV-positive patients is likely to become more complex as people age, developing multiple medical conditions thus requiring polypharmacy. We undertook a casenote review interview on antiretroviral therapy (ART) audit the safety devolving statin prescribing general practitioners (GPs). Of 26 only 50% had their successfully been devolved GPs. Many...
Abstract Background SARS-CoV-2 (COVID-19) has disrupted healthcare service delivery globally. CAB+RPV LA is a novel, long-acting antiretroviral therapy (ART) currently in development and administered intramuscularly monthly or every 2 months by provider. COVID-19 the resultant restrictions on access to some clinical trial sites presents challenges continuous (‘implementation fidelity’) of during pandemic. Methods Descriptive analyses were conducted using aggregated data from ongoing trials...
Objectives: The objective of this study was to describe the real-world use and effectiveness dolutegravir-based regimens (DBRs) in routine clinical practice United Kingdom.Methods: Retrospective analysis conducted using data from four National Health Service trusts Climate-HIV, an electronic case record system. Eligible patients were aged ≥18 years with HIV-1 infection who prescribed a DBR December 2012 March 2018. Outcome measurements accessed at initiation weeks 24, 48 96 last recorded...